HC Wainwright Cuts BioNTech (NASDAQ:BNTX) Price Target to $138.00

BioNTech (NASDAQ:BNTX) had its price target cut by HC Wainwright from $145.00 to $138.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BioNTech’s Q4 2025 earnings at $0.51 EPS, Q1 2026 earnings at ($2.23) EPS, Q2 2026 earnings at ($2.25) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at $0.88 EPS and FY2026 earnings at ($5.35) EPS.

A number of other equities analysts also recently commented on BNTX. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Citigroup reissued a “buy” rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Morgan Stanley cut their price target on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 6th. BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, Truist Financial reissued a “buy” rating and set a $155.00 price objective (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech has an average rating of “Moderate Buy” and an average price target of $137.86.

BioNTech Trading Down 0.5%

BNTX opened at $104.40 on Monday. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $101.79 and its two-hundred day moving average is $107.84. The company has a market capitalization of $25.10 billion, a P/E ratio of -30.71 and a beta of 1.29. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its position in BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after buying an additional 150 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of BioNTech during the 4th quarter worth about $1,118,000. Charles Schwab Investment Management Inc. grew its position in shares of BioNTech by 39.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company’s stock valued at $21,349,000 after acquiring an additional 53,319 shares during the period. Vontobel Holding Ltd. increased its stake in shares of BioNTech by 24.6% in the 4th quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company’s stock valued at $2,437,000 after purchasing an additional 4,227 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of BioNTech in the 4th quarter valued at about $584,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.